Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Naltrexone augmentation in OCD: A double-blind placebo-controlled cross-over study
Current treatments for Obsessive Compulsive Disorder ( OCD ) rely primarily on serotonergic mechanisms . However , approximately 30 % of patients do not respond to serotonin reuptake inhibitors and remain chronically ill . Given the behavioral similarities between some of the compulsive behaviors in OCD and addiction , we hypothesized that the opioid antagonist naltrexone might attenuate compulsions in OCD as well . The effect of naltrexone augmentation to SRI was compared to placebo in 10 OCD out patients who had not responded to an adequate dose of SSRI or clomipramine for at least 2 months . Participants underwent 5 weeks of treatment with naltrexone or placebo ( and 1 week of tapering ) in a r and omized , double-blind , cross-over design . Patients were evaluated weekly using the Y-BOCS , CGI , HAM-A , and MADRS scales . A two-way repeated measures MANOVA revealed no significant effect for Y-BOCS . However , while receiving naltrexone , patients had significantly higher scores on CGI , MADRS and HAM-A as compared to placebo . The lack of significant findings on OC symptoms could be due to either ceiling effect or alternatively , due to a non-specific exacerbation on anxiety and depression but not on OC symptoms
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .